Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

BACKGROUND: Anlotinib is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret. We aimed to evaluate the safety, pharmacokinetics, and antitumor activity of anlotinib in patients with advanced refractory solid tumors. METHOD...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Hematol Oncol
Autori principali: Sun, Yongkun, Niu, Wei, Du, Feng, Du, Chunxia, Li, Shuting, Wang, Jinwan, Li, Li, Wang, Fengqing, Hao, Yu, Li, Chuan, Chi, Yihebali
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2016
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5051080/
https://ncbi.nlm.nih.gov/pubmed/27716285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0332-8
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi